[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341644-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341644-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","grp78-inhibitor-yum70-upregulates-4e-bp1-and-suppresses-c-myc-expression-and-viability-of-oncogenic-c-myc-tumors","GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors","","The 78-kDa glucose regulated protein (GRP78) frequently elevated across tumors functions as a prognostic marker and a therapeutic target. While GRP78 is known as an ER chaperone that supports the unfolded protein response and protects from apoptosis, emerging evidence links it to oncoprotein regulation. This study identifies GRP78 suppression as a route to reduce MYC. GRP78 knockdown or inhibition by YUM70 or HA15 decreases c-MYC expression, induces apoptosis, and lowers viability in multiple models. Mechanistically, c-MYC repression occurs post-transcriptionally through increased 4E-BP1, which inhibits eIF4E-dependent translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/grp78-inhibitor-yum70-upregulates-4e-bp1-and-suppresses-c-myc-expression-and-viability-of-oncogenic-c-myc-tumors/341644/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/grp78-inhibitor-yum70-upregulates-4e-bp1-and-suppresses-c-myc-expression-and-viability-of-oncogenic-c-myc-tumors/341644.png","ImageObject",300,407,{"name":42,"@type":43},"Asher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main finding about GRP78 and c-MYC?","Question",{"text":63,"@type":64},"GRP78 suppression or inhibition reduces c-MYC expression. This reduction leads to apoptosis and loss of tumor cell viability in oncogenic c-MYC models.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do YUM70 and HA15 affect c-MYC at the molecular level?",{"text":68,"@type":64},"The study shows c-MYC suppression is post-transcriptional. YUM70 and HA15 upregulate 4E-BP1, which targets eIF4E and limits c-MYC translation initiation.",{"name":70,"@type":61,"acceptedAnswer":71},"Which experimental models were used to observe these effects?",{"text":72,"@type":64},"Effects were observed in 2D cell culture, 3D spheroid models, and xenograft models, including cisplatin-resistant head and neck cancer clones.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341644,1790177526,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Neoplasia 55 (2024) 101020  \nContents lists available at ScienceDirect  \nNeoplasia  \njournal [homepage:](homepage: www.elsevier.com/locate/neo)[ www.elsevier.com/locate/neo](homepage: www.elsevier.com/locate/neo)  \n| Original Research\u003Cbr>GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors |  |  | |\n| --- | --- | --- | --- |\n| Vicky Yamamoto a, b , Dat P. Ha a, b, Ze Liu a, b , Miller Huang c , Soma Samantad , Nouri Neamati d , Amy S. Lee a, b, *\u003Cbr>a Department of Biochemistry and Molecular Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States b Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States\u003Cbr>c Department of Pediatrics, Children’s Hospital of Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, United States d Department of Medicinal Chemistry, College of Pharmacy, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, United States |  |  |  |\n| A R T I C L E I N F O |  | A B S T R A C T |  |\n| Keywords: GRP78\u003Cbr>MYC\u003Cbr>Small molecule inhibitors YUM70\u003Cbr>4E-BP1\u003Cbr>Head and neck cancer Pancreatic cancer Breast cancer |  | The 78-kDa glucose regulated protein (GRP78) commonly upregulated in a wide variety of tumors is an important prognostic marker and a promising target for suppressing tumorigenesis and treatment resistance. While GRP78 is well established as a major endoplasmic reticulum (ER) chaperone with anti-apoptotic properties and a master regulator of the unfolded protein response, its new role as a regulator of oncoprotein expression is just emerging. MYC is dysregulated in about 70 % of human cancers and is the most commonly activated oncoprotein. However, despite recent advances, therapeutic targeting of MYC remains challenging. Here we identify GRP78 as a new target for suppression of MYC expression. Using multiple MYC-dependent cancer models including head and neck squamous cell carcinoma and their cisplatin-resistant clones, breast and pancreatic adenocarcinoma, our studies revealed that GRP78 knockdown by siRNA or inhibition of its activity by small molecule inhibitors (YUM70 or HA15) reduced c-MYC expression, leading to onset of apoptosis and loss of cell viability. This was observed in 2D cell culture, 3D spheroid and in xenograft models. Mechanistically, we determined that the suppression of c-MYC is at the post-transcriptional level and that YUM70 and HA15 treatment potently upregulated the eukaryotic translation inhibitor 4E-BP1, which targets eIF4E critical for c-MYC translation initiation. Furthermore, knock-down of 4E-BP1 via siRNA rescued YUM70-mediated c-MYC suppression. As YUM70 is also capable of suppressing N-MYC expression, this study offers a new approach to suppress MYC protein expression through knockdown or inhibition of GRP78. |  |\n\nIntroduction  \nThe 78-kDa glucose regulated protein (GRP78), also referred to as HSPA5/BiP, is a multifunctional protein that maintains cellular homeostasis in normal cells and tissues, however, its induction under pathological stress conditions can impact a wide range of human diseases, including cancer [1–7]. GRP78 is a well-established luminal endoplasmic reticulum (ER) chaperone which plays a critical role in ER protein quality control as a key regulator of the unfolded protein response (UPR) [8,9]. Subsequently, it was discovered that under stress, GRP78 can be translocated to the cell surface and in partnership with multiple cell surface co-receptors, exert additional effects on growth, signaling and viral entry and infectivity [6,10–15]. Recently, GRP78 was  \ndiscovered to be able to translocate to the nucleus under stress and acts as a transcriptional regulator to adopt an invasive phenotype [16]. These discoveries greatly expand the function of GRP78 beyond the ER, which continues to evolve.  \nGRP78 is highly up","cbCaimE6U7bTbL1R","https://ap.wps.com/l/cbCaimE6U7bTbL1R","pdf",10245568,12,"English","# Introduction\n## GRP78 functions in cancer and therapy resistance\n## GRP78 as a regulator of oncogenic proteins including MYC","[{\"question\":\"What is the main finding about GRP78 and c-MYC?\",\"answer\":\"GRP78 suppression or inhibition reduces c-MYC expression. This reduction leads to apoptosis and loss of tumor cell viability in oncogenic c-MYC models.\"},{\"question\":\"How do YUM70 and HA15 affect c-MYC at the molecular level?\",\"answer\":\"The study shows c-MYC suppression is post-transcriptional. YUM70 and HA15 upregulate 4E-BP1, which targets eIF4E and limits c-MYC translation initiation.\"},{\"question\":\"Which experimental models were used to observe these effects?\",\"answer\":\"Effects were observed in 2D cell culture, 3D spheroid models, and xenograft models, including cisplatin-resistant head and neck cancer clones.\"}]","GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumors | PDF",1790042960,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35b7f3bd25a61a5983677f9e2cea90f3.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86f09e0d041007ab2718f1a597238868.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eef9aac78268f95ee6c9bd7cdd49c362.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/404674b2f018b712cce9240f0fe7a2f7.webp",980,1306]